Today before the opening
bell, MissionIR announced that a new audio interview with VolitionRx, Ltd.
(OTCQB: VNRX) President and CEO Cameron Reynolds had been published online. The
entirety of the interview can be found at:
http://vnrx.missionir.com/interview.html.
VolitionRx is a publicly
held cancer diagnostics company that is concentrating its efforts on bringing
to market inexpensive, accurate, and minimally invasive cancer detection blood
tests that it has developed. Initially, the company is focusing on marketizing
diagnostic testing for colorectal cancer, which is the third most commonly
diagnosed cancer in the United States. Recently, a clinical study of some
16,000 patients was started to assess the accuracy of the company’s blood test.
Other plans are in place to develop diagnostic testing for other cancers in
addition to the detection of colorectal cancer.
Commenting on this
development, Mr. Reynolds said, “Being a small company and colorectal being a
multi-billion dollar market in itself, we’re focusing on getting product out
for that. But it’s certainly something we’d be very keen to expand into other
cancers as soon as we’re through the process of developing this diagnostic for
colorectal cancer.”
He also discussed the strong
accuracy of the company’s blood-based tests as well as his own professional
background and those of the company’s management and scientific teams. Mr.
Reynolds himself holds over 17 years’ entrepreneurial executive expertise in
mining and biotechnology companies, with extensive experience in the
management, structuring, and strategic planning of start-up companies. As a
whole, both teams collectively have decades of related experience and industry
success.
The company’s President and
CEO then touched upon recent company milestones and expectations and goals for
2014. He commented, “It’s been a very pivotal year for the company and next
year we’ll begin to get the results from this large clinical trial coming
through, so there are some very large data points coming in the first few
quarters of the year, which if they continue to go well will be
transformational for the company and really put us on the map as a very stable,
technologically superior platform for detecting colorectal cancer.”
Mr. Reynolds then continued,
“We’re beginning the process next year of beginning legal ability to sell our
tests in Europe and start the process of U.S. FDA trials.”
Wrapping it all up, he then
noted that VolitionRx aims to uplist to a major stock exchange in the second
half of 2014 to fully access capital markets and continue company growth.
For more information about
VolitionRx, please visit: www.VolitionRx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
